Metastatic Endometrial Cancer Clinical Trials

12 clinical trials for Metastatic Endometrial Cancer across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. — RECRUITING · PHASE1
• A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER, GLOBAL STUDY OF PUXITATUG SAMROTECAN (AZD8205) MONOTHERAPY VERSUS PHYSICIAN¿S CHOICE OF CHEMOTHERAPY IN PARTICIPANTS WITH B7-H4-SELECTED ADVANCED/METASTATIC ENDOMETRIAL CANCER WHO PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY AND ANTI-PD-1/ANTI-PD-L1 THERAPY (BLUESTAR-ENDOMETRIAL01) — RECRUITING · PHASE3
• A RANDOMIZED PHASE 2 STUDY OF CABOZANTINIB IN COMBINATION WITH NIVOLUMAB IN ADVANCED, RECURRENT METASTATIC ENDOMETRIAL CANCER — RECRUITING · PHASE2
• Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer — COMPLETED · PHASE2
• A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors — TERMINATED · PHASE1
• Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer — TERMINATED · PHASE1
• Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study — COMPLETED
• Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer — TERMINATED · PHASE1
• RANDOMIZED CONTROLLED STUDY COMPARING AEZS 108 WITH DOXORUBICIN AS SECOND LINE THERAPY FOR LOCALLY ADVANCED, RECURRENT OR METASTATIC ENDOMETRIAL CANCER. — COMPLETED

Refine this search